Manual Therapy/Exercises vs. Physiotherapy/Back School vs. Waiting List in Patients With Chronic Low Back Pain

Sponsor
Charite University, Berlin, Germany (Other)
Overall Status
Recruiting
CT.gov ID
NCT05843149
Collaborator
(none)
108
1
3
19
5.7

Study Details

Study Description

Brief Summary

A randomized controlled trial for patients with chronic low back pain with two treatment arms and one waiting list control group. Primary outcome is pain intensity on VAS.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Manual Therapy/Exercises
  • Behavioral: Physiotherapy/Back School
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
108 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Manual Therapy/Exercises vs. Physiotherapy/Back School vs. Waiting List in Patients With Chronic Low Back Pain - a Randomized Controlled Trial
Actual Study Start Date :
May 2, 2023
Anticipated Primary Completion Date :
Jul 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Manual Therapy/Exercises

Three individual therapy sessions and nine group sessions manual therapy/exercises of 60 min. duration under the guidance of a trained therapist.

Behavioral: Manual Therapy/Exercises
Three individual therapy sessions and nine group sessions manual therapy/exercises of 60 min. duration under the guidance of a trained therapist.

Experimental: Physiotherapy/Back School

Three individual therapy sessions and nine group sessions physiotherapy/back school of 60 min. duration under the guidance of a trained therapist.

Behavioral: Physiotherapy/Back School
Three individual therapy sessions and nine group sessions physiotherapy/back school of 60 min. duration under the guidance of a trained therapist.

No Intervention: Waiting List

Study arm 3 consists of a waiting list control group, combined with the offer to participate in one of the above mentioned interventions after 6 months.

Outcome Measures

Primary Outcome Measures

  1. Change from baseline in average pain intensity in previous week [3 months]

    Intensity of pain in previous week as measured on a 100 mm visual analog scale (0-100).

Secondary Outcome Measures

  1. Change from baseline for back pain specific disability [3 months, 6 months]

    Use of standardized Roland Morris Disability Questionnaire (RMDQ) to assess back pain specific disability. The scale ranges from 0 to 100, where 0 is the lowest level and 100 is the highest level.

  2. Change from baseline in average pain intensity in previous week [6 months]

    Intensity of pain in previous week as measured on a 100 mm visual analog scale (0-100).

  3. Change from baseline in pain bothersomeness in previous week [3 months, 6 months]

    Bothersomeness in previous week as measured on a 100 mm visual analog scale (0-100).

  4. Change from baseline in pain medication use in the previous week [3 months, 6 months]

    Specific self-reported pain medication use in previous week.

  5. Change from baseline for health related quality of life [3 months, 6 months]

    Use of standardized Short Form 36 Health Survey (SF-36). The scale ranges from 0 to 100, where 0 is the lowest level and 100 is the highest level.

  6. Change from baseline for pain self-efficacy [3 months, 6 months]

    Use of standardized Pain Self-Efficacy Questionnaire (PSEQ). The scale ranges from 0 to 100, where 0 is the lowest level and 100 is the highest level.

  7. Change from baseline for work productivity [3 months, 6 months]

    Use standardized Work Productivity and Activity Impairment Questionnaire (WPAI) to assess employment status and productivity. The scale ranges from 0 to 100, where 0 is the lowest level and 100 is the highest level.

  8. Change from baseline for anxiety and depression [3 months, 6 months]

    Use of standardized Hospital Anxiety and Depression Scale (HADS). The scale ranges from 0 to 100, where 0 is the lowest level and 100 is the highest level.

Other Outcome Measures

  1. Number of participants with adverse events as a measure of safety and treatment adherence [3 months, 6 months]

    Identify and assess self reported and unanticipated adverse events over the course of the study as a measure of safety and treatment adherence.

  2. Treatment adherence (class/session attendance) [3 months, 6 months]

    Assess treatment adherence according to attendance during 12 week intervention period.

  3. App via mobile phones [3 times daily within baseline and 6 months]

    Use of an mobile app to assess back pain intensity, pain medication, practice time

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • pre-existing and specialist confirmed diagnosis of chronic low back pain for at least 3 months prior to inclusion

  • Average pain intensity with at least 40 mm on the VAS from 0 to 100 mm and pain on at least 5 of 7 weekdays in the last 3 months.

Exclusion criteria:
  • Regular own exercise practice for the treatment of back pain (including yoga and other interventions)

  • Invasive spinal procedures within the past 6 weeks or planned within the next 10 weeks

  • Acute disc herniation (diagnosed within the last 3 months)

  • Congenital deformities of the lumbar spine

  • Rheumatoid arthritis

  • Fibromyalgia

  • Ankylosing spondylitis

  • Severe comorbidities

  • Pregnancy/lactation

  • Current participation in another clinical trial

Contacts and Locations

Locations

Site City State Country Postal Code
1 Charite University Berlin Germany 14109

Sponsors and Collaborators

  • Charite University, Berlin, Germany

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Andreas Michalsen, Principal Investigator, Charite University, Berlin, Germany
ClinicalTrials.gov Identifier:
NCT05843149
Other Study ID Numbers:
  • NHKManual
First Posted:
May 6, 2023
Last Update Posted:
May 6, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 6, 2023